{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:30:34Z","timestamp":1787758234443,"version":"build-2784847793"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background and Aim:<\/jats:title>\n                    <jats:p>The aim of the study was to examine the demographic, clinical features, treatment responses, and outcomes of Hodgkin lymphoma (HL) patients and to investigate the factors affecting their survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>A retrospective analysis was made of patients diagnosed with HL in our department between 2009 and 2019. Treatment regimen, treatment response, and follow-up times were recorded for all patients. Using these data, complete response (CR) rates, overall survival (OS), and progression-free survival (PFS) were calculated. The effects of parameters on survival were investigated with Cox regression analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Evaluation was made of 60 patients with a median age of 33.5 years [18.0\u201380.0] and mean follow-up duration of 29.34 \u00b1 23.64 months. Median OS and PFS could not be reached with a mean OS of 85.6 months, and PFS of 71.7 months at the final visit. Only initial leukocyte and neurophil count were determined to have a statistically significant impact on survival (OR = 1.004;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.031 vs OR = 0.996;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.036).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In HL patients, in addition to the many prognostic scoring systems, leukocyte and neutrophil count can be used as an independent prognostic parameter. Patients with higher leukocyte and lower neutrophil counts at the time of diagnosis should be managed more carefully.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/njcp.njcp_175_22","type":"journal-article","created":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T13:09:27Z","timestamp":1660655367000},"page":"1332-1337","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["The Prognost\u0131C Significance of Blood Counts in Patients with Hodgkin Lymphoma"],"prefix":"10.4103","volume":"25","author":[{"given":"M R","family":"Aras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Albayrak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Yildiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Maral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HB A","family":"Ozturk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Tiglioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Tiglioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Saglam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20-20240907","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3322\/caac.21438","article-title":"Hodgkin lymphoma: A review and update on recent progress","volume":"68","author":"Shanbhag","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"R2-20-20240907","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/bjh.15614","article-title":"Diagnosis of Hodgkin lymphoma in the modern era","volume":"184","author":"Wang","year":"2019","journal-title":"Br J Haematol"},{"key":"R3-20-20240907","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/ajh.25071","article-title":"Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management","volume":"93","author":"Ansell","year":"2018","journal-title":"Am J Hematol"},{"key":"R4-20-20240907","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1182\/blood-2017-09-772673","article-title":"Transplant strategies in relapsed\/refractory Hodgkin lymphoma","volume":"131","author":"Shah","year":"2018","journal-title":"Blood"},{"key":"R5-20-20240907","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1158\/1078-0432.CCR-16-1387","article-title":"Nivolumab in the treatment of Hodgkin lymphoma","volume":"23","author":"Ansell","year":"2017","journal-title":"Clin Cancer Res"},{"key":"R6-20-20240907","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1182\/blood-2017-10-772665","article-title":"Balancing risk and benefit in early-stage classical Hodgkin lymphoma","volume":"131","author":"Br\u00f6ckelmann","year":"2018","journal-title":"Blood"},{"key":"R8-20-20240907","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S0140-6736(12)60035-X","article-title":"Hodgkin's lymphoma in adults","volume":"380","author":"Townsend","year":"2012","journal-title":"Lancet"},{"key":"R10-20-20240907","doi-asserted-by":"crossref","first-page":"608","DOI":"10.6004\/jnccn.2017.0064","article-title":"Hodgkin lymphoma version 1.2017, NCCN clinical practice guidelines in oncology","volume":"15","author":"Hoppe","year":"2017","journal-title":"J Natl Compr Cancer Netw"},{"key":"R11-20-20240907","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1186\/s12885-019-5552-1","article-title":"Prognostic value of lymphocyte-monocyte ratio at diagnosis in Hodgkin lymphoma: A meta-analysis","volume":"19","author":"Lee","year":"2019","journal-title":"BMC Cancer"},{"key":"R12-20-20240907","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.4067\/S0034-98872019001201553","article-title":"Recuento absoluto de monocitos como par\u00e1metro pron\u00f3stico en linfoma difuso de c\u00e9lulas B grandes","volume":"147","author":"Ir\u0131go\u00edn","year":"2019","journal-title":"Rev M\u00e9d Chile"},{"key":"R13-20-20240907","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/bjh.15054","article-title":"Pre-treatment neutrophil\/lymphocyte ratio and platelet\/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma","volume":"180","author":"Reddy","year":"2018","journal-title":"Br J Haematol"},{"key":"R14-20-20240907","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2478\/ahp-2020-0008","article-title":"Prediction of survival in non-Hodgkin lymphoma based on markers of systemic inflammation, anemia, hypercoagulability, dyslipidemia, and Eastern Cooperative Oncology Group performance status","volume":"51","author":"Dzis","year":"2020","journal-title":"Acta Haematol Pol"},{"key":"R15-20-20240907","doi-asserted-by":"crossref","first-page":"e898","DOI":"10.1634\/theoncologist.2018-0629","article-title":"Pretreatment hemoglobin as an independent prognostic factor in primary central nervous system lymphomas","volume":"24","author":"Le","year":"2019","journal-title":"Oncologist"},{"key":"R16-20-20240907","first-page":"181","article-title":"Anemia associated with worse outcome in diffuse large b-cell lymphoma patients: A single-center retrospective study","volume":"35","author":"Matsumoto","year":"2018","journal-title":"Turk J Haematol"},{"key":"R17-20-20240907","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1080\/09537104.2018.1499889","article-title":"Novel prognostic index based on hemoglobin level and platelet count for diffuse large B-cell lymphoma, not otherwise specified in the R-CHOP era","volume":"30","author":"Nakayama","year":"2019","journal-title":"Platelets"},{"key":"R18-20-20240907","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1159\/000495337","article-title":"Prognostic value of platelet count in patients with peripheral T cell lymphoma","volume":"141","author":"Choi","year":"2019","journal-title":"Acta Haematol"},{"key":"R19-20-20240907","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced Hodgkin's disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N Engl J Med"},{"key":"R20-20-20240907","first-page":"1258","article-title":"Prognostic factors and outcome of ABVD chemotherapy in childhood Hodgkin Iymphoma: A single center experience","volume":"26","author":"Yoruk","year":"2019","journal-title":"Annals of Medical Research"}],"container-title":["Nigerian Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/njcp.njcp_175_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:10:27Z","timestamp":1787757027000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/njcp.njcp_175_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/njcp.njcp_175_22","relation":{},"ISSN":["1119-3077"],"issn-type":[{"value":"1119-3077","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]}}}